Enliven Therapeutics Inc Financials
This page shows Enliven Therapeutics Inc (ELVN) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 7 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Equity-funded research investment is expanding losses while keeping liabilities low and reported liquidity comparatively ample.
In FY2025, operating cash flow was-$70.3M against a net loss of-$103.7M ; that narrower cash shortfall means accounting losses include noncash or timing effects, although operations still consume cash. Between FY2024 and FY2025, financing inflows increased64.4% as shares outstanding increased22.0% , tying balance-sheet expansion to equity issuance rather than internally generated funds.
The expense profile remains development-led: FY2025 research and development was
Total equity reached
Financial Health Signals
Enliven Therapeutics Inc does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
Enliven Therapeutics Inc passes 3 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 2 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass.
Enliven Therapeutics Inc reported a net loss of $103.7M while operations used $70.3M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
Enliven Therapeutics Inc's EBITDA was -$119.4M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 14.5% from the prior year.
Enliven Therapeutics Inc reported -$103.7M in net income in fiscal year 2025. This represents a decrease of 16.5% from the prior year.
Enliven Therapeutics Inc earned -$1.83 per diluted share (EPS) in fiscal year 2025. This represents an increase of 3.2% from the prior year.
Not reported for fiscal year 2025.
Cash & Balance Sheet
Enliven Therapeutics Inc recorded an outflow of $70.5M in free cash flow in fiscal year 2025, representing a cash shortfall after capex. This represents an increase of 3.8% from the prior year.
Enliven Therapeutics Inc held $98.9M in cash as of fiscal year 2025; long-term debt is not reported for that period.
Not reported for fiscal year 2025.
Margins & Returns
Enliven Therapeutics Inc's ROE was -22.6% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 6.2 percentage points from the prior year.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Capital Allocation
Enliven Therapeutics Inc invested $85.9M in research and development in fiscal year 2025. This represents an increase of 6.3% from the prior year.
Enliven Therapeutics Inc invested $158K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 259.1% from the prior year.
Not reported for fiscal year 2025.
ELVN Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| R&D Expenses | $29.0M+40.2% | $20.7M | N/A | $18.2M-15.2% | $21.5M-13.7% | $24.9M | N/A | $21.3M |
| SG&A Expenses | $8.2M+15.1% | $7.1M | N/A | $6.9M-3.1% | $7.1M+4.3% | $6.8M | N/A | $5.8M |
| Operating Income | -$37.2M-33.7% | -$27.8M | N/A | -$25.1M+12.2% | -$28.6M+9.8% | -$31.7M | N/A | -$27.1M |
| Income Tax | N/A | N/A | N/A | $0 | $0 | N/A | N/A | $0 |
| Net Income | -$32.5M-37.5% | -$23.6M | N/A | -$20.1M+20.5% | -$25.3M+11.2% | -$28.5M | N/A | -$23.2M |
| EPS (Diluted) | -$0.49-28.9% | -$0.38+20.8% | -$0.48-50.0% | -$0.32+34.7% | -$0.49+14.0% | -$0.57-23.9% | -$0.46+4.2% | -$0.48 |
Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, Interest Expense.
ELVN Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $910.2M+95.8% | $464.9M-2.4% | $476.2M-3.0% | $490.9M-2.6% | $503.9M+66.5% | $302.6M-7.1% | $325.8M+6.7% | $305.4M |
| Current Assets | $907.3M+95.9% | $463.1M-2.5% | $474.9M-1.6% | $482.7M-2.6% | $495.6M+68.4% | $294.3M-7.5% | $318.1M+7.1% | $297.0M |
| Cash & Equivalents | $135.5M+2.5% | $132.2M+33.7% | $98.9M-2.8% | $101.7M-14.8% | $119.4M+17.4% | $101.7M-18.1% | $124.1M+23.4% | $100.6M |
| Total Liabilities | $15.1M+31.2% | $11.5M-30.7% | $16.6M+12.3% | $14.8M-4.3% | $15.4M+8.0% | $14.3M-10.3% | $15.9M-6.5% | $17.0M |
| Current Liabilities | $14.2M+23.3% | $11.5M-30.7% | $16.6M+13.1% | $14.7M-3.7% | $15.2M+8.9% | $14.0M-12.2% | $15.9M-6.5% | $17.0M |
| Total Equity | $895.1M+97.4% | $453.4M-1.4% | $459.6M-3.5% | $476.1M-2.5% | $488.5M+69.4% | $288.3M-7.0% | $309.8M+7.4% | $288.4M |
| Retained Earnings | -$403.3M-8.8% | -$370.8M-6.8% | -$347.2M-9.3% | -$317.5M-6.8% | -$297.4M-9.3% | -$272.0M-11.7% | -$243.5M-10.5% | -$220.3M |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.
ELVN Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$18.5M+3.9% | -$19.3M-21.8% | -$15.8M-19.3% | -$13.3M+22.1% | -$17.1M+29.3% | -$24.1M-40.2% | -$17.2M-41.1% | -$12.2M |
| Capital Expenditures | $99K | $0 | $0-100.0% | -$1K-99.3% | $139K+595.0% | $20K | $0-100.0% | $22K |
| Free Cash Flow | -$18.6M+3.4% | -$19.3M-21.8% | -$15.8M-19.3% | -$13.3M+22.8% | -$17.2M+28.8% | -$24.1M-40.4% | -$17.2M-40.8% | -$12.2M |
| Investing Cash Flow | -$441.6M-1138.3% | $42.5M+243.5% | $12.4M+405.1% | -$4.1M+97.8% | -$183.6M-12965.4% | $1.4M+96.3% | $727K-95.1% | $14.8M |
| Financing Cash Flow | $463.4M+4509.7% | $10.1M+1513.6% | $623K+269.3% | -$368K-100.2% | $218.4M+93223.9% | $234K-99.4% | $40.0M+3478.5% | $1.1M |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
ELVN Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Return on Equity | -3.6%+1.6pp | -5.2% | N/A | -4.2%+1.0pp | -5.2%+4.7pp | -9.9% | N/A | -8.0% |
| Return on Assets | -3.6%+1.5pp | -5.1% | N/A | -4.1%+0.9pp | -5.0%+4.4pp | -9.4% | N/A | -7.6% |
| Current Ratio | 64.07+23.8x | 40.32+11.7x | 28.66-4.3x | 32.95+0.4x | 32.58+11.5x | 21.06+1.1x | 19.99+2.5x | 17.44 |
| Debt-to-Equity | 0.020.0x | 0.030.0x | 0.040.0x | 0.030.0x | 0.030.0x | 0.050.0x | 0.050.0x | 0.06 |
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, FCF Margin.
Similar Companies
Where Enliven Therapeutics Inc Ranks
Frequently Asked Questions
Is Enliven Therapeutics Inc profitable?
No, Enliven Therapeutics Inc (ELVN) reported a net income of -$103.7M in fiscal year 2025.
What is Enliven Therapeutics Inc's EBITDA?
Enliven Therapeutics Inc (ELVN) had EBITDA of -$119.4M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Enliven Therapeutics Inc's return on equity (ROE)?
Enliven Therapeutics Inc (ELVN) has a return on equity of -22.6% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Enliven Therapeutics Inc's free cash flow?
Enliven Therapeutics Inc (ELVN) recorded an outflow of $70.5M in free cash flow during fiscal year 2025. This represents a 3.8% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Enliven Therapeutics Inc's operating cash flow?
Enliven Therapeutics Inc (ELVN) recorded an outflow of $70.3M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Enliven Therapeutics Inc's total assets?
Enliven Therapeutics Inc (ELVN) had $476.2M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Enliven Therapeutics Inc's capital expenditures?
Enliven Therapeutics Inc (ELVN) invested $158K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Enliven Therapeutics Inc spend on research and development?
Enliven Therapeutics Inc (ELVN) invested $85.9M in research and development during fiscal year 2025.
What is Enliven Therapeutics Inc's current ratio?
Enliven Therapeutics Inc (ELVN) had a current ratio of 28.66 as of fiscal year 2025, which is generally considered healthy.
What is Enliven Therapeutics Inc's debt-to-equity ratio?
Enliven Therapeutics Inc (ELVN) had a debt-to-equity ratio of 0.04 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Enliven Therapeutics Inc's return on assets (ROA)?
Enliven Therapeutics Inc (ELVN) had a return on assets of -21.8% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
How does Enliven Therapeutics Inc's liquidity compare with its operating cash outflow?
At the end of fiscal year 2025, Enliven Therapeutics Inc (ELVN) held $462.6M in cash, cash equivalents and investments, and reported an operating cash outflow of $70.3M over that year. Dividing the one by the other, the reported balance equals about 79 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
What is Enliven Therapeutics Inc's Piotroski F-Score?
Enliven Therapeutics Inc (ELVN) has a Piotroski F-Score of 3 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Enliven Therapeutics Inc's earnings high quality?
Enliven Therapeutics Inc (ELVN) reported a net loss of $103.7M while operations used $70.3M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.